Trends in survival for patients with metastatic soft-tissue sarcoma

Cancer

Volumn 117, Issue 5, 2011, Pages 1049-1054

  Italiano, Antoine ^a   Mathoulin Pelissier, Simone ^a,b   Le Cesne, Axel ^c   Terrier, Philippe ^c   Bonvalot, Sylvie ^c   Collin, Françoise ^d   Michels, Jean Jacques ^e   Blay, Jean Yves ^f   Coindre, Jean Michel ^a   Bui, Binh ^a  

^a INSTITUT BERGONIÉ   (France)

^b Institut National de al Santé et de la Recherche Médicale   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d Georges Francois Leclerc Center   (France)

^e François Baclesse Center   (France)

^f Centre L Berard   (France)

Author keywords

Advanced; Metastatic; Prognosis; Sarcoma; Survival

Indexed keywords

ADULT; ARTICLE; CANCER GRADING; CANCER RECURRENCE; FEMALE; FOLLOW UP; HUMAN; LEIOMYOSARCOMA; LIPOSARCOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT FIBROUS HISTIOCYTOMA; METASTASIS POTENTIAL; NERVE SHEATH TUMOR; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RHABDOMYOSARCOMA; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; FRANCE; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; NEOPLASM METASTASIS; RETROSPECTIVE STUDIES; SARCOMA; SOFT TISSUE NEOPLASMS; SURVIVAL ANALYSIS; SURVIVAL RATE; YOUNG ADULT;

EID: 79952035127     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25538     Document Type: Article

References (19)

1. Coindre JM, Terrier P, Guillou L, et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer. 2001;91:1914-1926. (Pubitemid 32424119)
2. Fletcher C, Unni K, Mertens F, eds. World Health Organization Classification of Tumours Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon, France: IARC Press; 2002.
3. Van Glabbeke M, van Oosterom AT, Oosterhuis JW, et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2185 patients treated with anthracycline-containing first-line regimens - a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group study. J Clin Oncol. 1999;17:150-157. (Pubitemid 29022388)
4. Karavasilis V, Seddon BM, Ashley S, Al-Muderis O, Fisher C, Judson I. Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients. Cancer. 2008;112:1585-1591. (Pubitemid 351441172)
5. Trojani M, Contesso G, Coindre JM, et al. Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system. Int J Cancer. 1984;33:37-42. (Pubitemid 14223231)
6. Shuster JJ. Median follow-up in clinical trials. J Clin Oncol. 1991;9:191-192.
7. Derre J, Lagace R, Nicolas A, et al. Leiomyosarcomas and most malignant fibrous histiocytomas share very similar comparative genomic hybridization imbalances: an analysis of a series of 27 leiomyosarcomas. Lab Invest. 2001;81:211-215. (Pubitemid 32176385)
8. Coindre JM, Hostein I, Maire G, et al. Inflammatory malignant fibrous histiocytomas and dedifferentiated liposarcomas: histological review, genomic profile, and MDM2 and CDK4 status favour a single entity. J Pathol. 2004;203:822-830. (Pubitemid 38961569)
9. Berselli M, Fiore M, Grosso F, et al. Primary extremity soft tissue sarcoma: a more liberal multimodality approach may have improved survival over time [abstract]. Paper presented at: 15th Annual Meeting of the Connective Tissue Oncology Society; Miami Beach, FL; November 5-7, 2009. Abstract 39308.
10. Sleijfer S, Seynaeve C, Verweij J. Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care. Oncologist. 2005;10:833-841. (Pubitemid 43152701)
11. Tascilar M, Loos WJ, Seynaeve C, Verweij J, Sleijfer S. The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas. Oncologist. 2007;12:1351-1360. (Pubitemid 350232609)
12. McArthur G. Molecularly targeted treatment for dermatofibrosarcoma protuberans. Semin Oncol. 2004;31(2 suppl 6):30-36. (Pubitemid 38879420)
13. Rutkowski P, Van Glabbeke M, Rankin CJ, et al. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of 2 phase II clinical trials. J Clin Oncol. 2010;28:1772-1779.
14. Fata F, O'Reilly E, Ilson D, et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer. 1999;86:2034-2037.
15. Penel N, Bui BN, Bay JO, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX study. J Clin Oncol. 2008;26:5269-5274.
16. Patel SR, Gandhi V, Jenkins J, et al. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol. 2001;19:3483-3489. (Pubitemid 32730085)
17. Pautier P, Bui Nguyen B, Penel N, et al. Final results of an FNCLCC French Sarcoma Group multicenter randomized phase II study of gemcitabine (G) versus gemcitabine and docetaxel (G+D) in patients with metastatic or relapsed leiomyosarcoma (LMS) [abstract]. J Clin Oncol. 2009;27:15S. Abstract 10527.
18. Grosso F, Jones RL, Demetri GD, et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol. 2007;8:595-602. (Pubitemid 46995623)
19. Italiano A, Delcambre C, Hostein I, et al. Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa. Ann Oncol. 2010;21:1136-1137.